财中社11月1日电翰森制药(03692)发布公告,宣布其自主研发的B7-H3靶向抗体-药物偶联物HS-20093于2024年11月1日获得中国国家药品监督管理局批准,纳入突破性治疗药物,适应症为经过标准一线治疗后进展的广泛期小细胞肺癌(ES-SCLC)。
HS-20093是一种新型B7-H3靶向ADC,结合了全人源抗B7-H3单抗与拓扑异构酶抑制剂有效载荷,正在中国进行针对小细胞肺癌的III期临床研究,同时还涉及多项I期和II期研究,适用于肉瘤、头颈癌等其他实体瘤。此外,翰森制药与GSK签订了许可协议,授予其全球独占许可,以开发、生产及商业化HS-20093,GSK目前正在进行全球I期临床试验。
(文章来源:财中社)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.